Suga S, Tsunekawa H, Washino M, Makino N, Tamura Z, Goto S
Gastroenterol Jpn. 1977;12(2):20-9. doi: 10.1007/BF02773621.
Investigations were made on the survivals of 81 patients with advanced gastric cancer. Of these, 55 patients were treated with a combination chemotherapy of mitomycin C, 5-fluorouracil, and cytosine arabinoside (i.e., MFC therapy). Another 26 cases were treated with immunochemotherapy of MFC plus OK-432, an immunotherapeutic agent. Fifty percent survival times were 5.4 months for the MFC group, and 7.5 months for the MFC plus OK-432 group. One year survival rates of each group were 13 and 35 percent, respectively. The two year survival was null for the MFC group, and 13 percent for the MFC plus OK-432 group. Statistical analysis revealed that the survival curve of the MFC plus OK-432 decreased more slowly as compared with that of the MFC (p less than 0.05). In other words, the patients treated with MFC plus OK-432 showed a significantly longer survivals compared to the patients treated with MFC alone. Some cases were also presented for the better understanding of the immunochemotherapy of MFC plus OK-432.
对81例晚期胃癌患者的生存情况进行了调查。其中，55例患者接受了丝裂霉素C、5-氟尿嘧啶和阿糖胞苷的联合化疗（即MFC疗法）。另外26例患者接受了MFC加免疫治疗剂OK-432的免疫化疗。MFC组的50%生存时间为5.4个月，MFC加OK-432组为7.5个月。每组的一年生存率分别为13%和35%。MFC组的两年生存率为零，MFC加OK-432组为13%。统计分析显示，与MFC组相比，MFC加OK-432组的生存曲线下降更慢（p小于0.05）。换句话说，与单独接受MFC治疗的患者相比，接受MFC加OK-432治疗的患者生存期明显更长。还列举了一些病例，以便更好地理解MFC加OK-432的免疫化疗。
